EUVIMEDEUVIMED entdecken
Crossref

New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis

Qing Sun, Kai Cheng, Xinlei Liao, Weijie Zhao, Chenqian Wang, Chaohong Wang, Jun Yan, Lingling Dong, Fen Wang, Guanglu Jiang, Hairong Huang, Zhenyong Guo und 1 weitere

Journal of Medical Microbiology · 2024

DOI: 10.1099/jmm.0.001825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2024. Verfasst von Qing Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medica…. Hauptthemen laut MEDLINE: Fluoroquinolones, Mycobacterium tuberculosis, Moxifloxacin, Levofloxacin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Beijing Public Health Experts Project, Beijing Tongzhou Municipal Science & Technology commission, Tongzhou Yunhe Project under Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pre-existing fluoroquinolones (FQs) resistance is a major threat in treating multidrug-resistant (MDR) tuberculosis. Sitafloxacin (Sfx) is a new broad-spectrum FQ. Hypothesis. Sfx is more active against drug-resistant Mycobacterium tuberculosis (Mtb) isolates.

Aim

To determine whether there is cross-resistance between Sfx and ofloxacin (Ofx), levofloxacin (Lfx) and moxifloxacin (Mfx) in MDR Mtb.

Methods

A total of 106 clinical Mtb isolates, including 23 pan-susceptible and 83 MDR strains, were analysed for Sfx, Lfx and Mfx resistance using MIC assay. The isolates were also subjected to whole-genome sequencing to analyse drug-resistant genes.

Results

Sfx exhibited the most robust inhibition activity against Mtb clinical isolates, with a MIC 50 of 0.0313 µg ml −1 and MIC 90 of 0.125 µg ml −1 , which was lower than that of Mfx (MIC 50 = 0.0625 µg ml −1 , MIC 90 = 1 µg ml −1 ) and Lfx (MIC 50 = 0.125 µg ml −1 , MIC 90 = 2 µg ml −1 ). We determined the tentative epidemiological cut-off values as 0.5 µg ml −1 for Sfx. Also, 8.43% (7/83), 43.37% (36/83), 42.17% (35/83) and 51.81% (43/83) MDR strains were resistant to Sfx, Mfx, Lfx and Ofx, respectively. Cross-resistance between Ofx, Lfx and Mfx was 80.43% (37/46). Only 15.22% (7/46) of the pre-existing FQs resistance isolates were resistant to Sfx. Among the 30 isolates with mutations in gyrA or gyrB , 5 (16.67%) were Sfx resistant. The combination of Sfx and rifampicin could exert partial synergistic effects, and no antagonism between Sfx and six clinically important anti-Mtb antibiotics was evident.

Conclusion

Sfx exhibited superior activity against MDR isolates comparing to Lfx and Mfx, and could potentially overcome the majority pre-existing FQs resistance in Mtb strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesMycobacterium tuberculosisMoxifloxacinLevofloxacinMicrobial Sensitivity TestsTuberculosis, Multidrug-ResistantDrug Resistance, Multiple, BacterialAntitubercular AgentsHumansWhole Genome Sequencing

Stichwörter der Autor:innen

Mycobacterium tuberculosisfluoroquinolonesmultidrug resistantsitafloxacin

Substanzen

FluoroquinolonesMoxifloxacinLevofloxacinAntitubercular Agentssitafloxacin

Autor:innen und Institutionen

  • National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beiji…
  • Pharmacy of Beijing Chest Hospital, Capital Medical University, Beijing, PR China.
  • The Administration Office of Clinical Trial, Beijing Chest Hospital, Capital Medical University, Beijing, PR China.

Förderung

  • Beijing Public Health Experts Project
  • Beijing Tongzhou Municipal Science & Technology commission
  • Tongzhou Yunhe Project under Grant

Zitieren

APA

Sun, Q., Cheng, K., Liao, X., Zhao, W., Wang, C., Wang, C., Yan, J., Dong, L., Wang, F., Jiang, G., Huang, H., Guo, Z., & Wang, G. (2024). New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001825

Vancouver

Sun Q, Cheng K, Liao X, Zhao W, Wang C, Wang C, et al. New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis. Journal of Medical Microbiology. 2024. doi:10.1099/jmm.0.001825

BibTeX
@article{Sun2024,
  author = {Sun, Qing and Cheng, Kai and Liao, Xinlei and Zhao, Weijie and Wang, Chenqian and Wang, Chaohong and Yan, Jun and Dong, Lingling and Wang, Fen and Jiang, Guanglu and Huang, Hairong and Guo, Zhenyong and Wang, Guirong},
  title = {New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis},
  journal = {Journal of Medical Microbiology},
  year = {2024},
  doi = {10.1099/jmm.0.001825}
}
Kostenlos starten →